BridgeBio Pharma (BBIO) Accumulated Expenses (2018 - 2026)

BridgeBio Pharma (BBIO) has 9 years of Accumulated Expenses data on file, last reported at $39.3 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 17.61% year-over-year to $39.3 million; the trailing twelve-month figure through Mar 2026 stood at $39.3 million (up 17.61% YoY), and the FY2025 full-year result was $76.7 million, up 31.5% from the prior year.
• Accumulated Expenses eased to $39.3 million in Q1 2026, from $76.7 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $76.7 million in Q4 2025 to a low of $3.9 million in Q1 2024.
• A 5-year average of $33.3 million and a median of $32.6 million in 2022 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses slumped 79.51% in 2024 and soared 765.16% in 2025, its largest moves.
• Tracing BBIO's Accumulated Expenses over 5 years: stood at $17.5 million in 2022, then soared by 227.83% to $57.4 million in 2023, then rose by 1.67% to $58.3 million in 2024, then jumped by 31.5% to $76.7 million in 2025, then sank by 48.71% to $39.3 million in 2026.
• Business Quant data shows BBIO's Accumulated Expenses at $39.3 million in Q1 2026, $76.7 million in Q4 2025, and $56.2 million in Q3 2025.